Intestinal inflammation research
1Cell and mouse colitis experiments investigate anti-inflammatory activity.
What does it do?
α-MSH-derived tripeptide studied for inflammation and antimicrobial biology, principally preclinically. No established broad clinical efficacy or safety profile.
Approved & studied uses
Community uses Reported, unvalidated
Inflammation and immunity
13Cytokine, autoimmune/joint and infection-response hypotheses.
Gut
13IBD, IBS, barrier and microbiome claims; not proven disease treatment.
Skin
13Psoriasis, dermatitis and wound models.
Nasal/respiratory
13Sinusitis, allergy and post-viral claims remain experimental.
Reasons people report using it; these do not establish benefit.13
Evidence limits
View research →Human efficacy, absorption, dose-response, and long-term safety.1
4 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Human safety gap
FDA identified no human exposure dataset for KPV drug products.2
No FDA-approved KPV product.
Molecular information
Amino-acid sequence
- Lys
- Pro
- Val
3 residues · N → C3
Length3 amino acids
Molecular weight · Da342.43 Da
Formula, sequence notation & identity
Molecular formulaC16H30N4O43
K–P–VH-Lys-Pro-Val-OH (KPV)
Free-base specification; acetate adds acetic acid. Amidated KPV is chemically distinct and should not be silently substituted.
Pharmacokinetics
How long does it stay in the body?
Unverified reference estimateNot independently confirmed
Reference half-life30 min12
Route / formulationSource page: Injectable. Exact PK route not verified.
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 2.5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Limited data
Source’s reported peak time: 3 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life15 min12
Route / formulationSource page: Oral. Exact PK route not verified.
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 1.25 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Limited data
Source’s reported peak time: 2 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life30 min12
Route / formulationSource page: Topical. Exact PK route not verified.
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects. A topical tab does not establish systemic elimination or duration of local skin effects.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 2.5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Limited data
Source’s reported peak time: 3 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life30 min12
Route / formulationSource page: Nasal. Exact PK route not verified.
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 2.5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Limited data
Source’s reported peak time: 3 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Preclinical anti-inflammatory signal
KPV reduced inflammatory signaling in cells and improved experimental mouse colitis measures. Human clinical benefit remains untested in the cited study.1
Additional research
At 100 μg/mL, cultured-cell lipid readouts decreased. Oral administration in high-fat-diet mice changed weight gain and lipid measures; no human metabolic benefit is established.4
Reported timelines
Reference & communityDays 1–3; weeks 1–3; 4–8
Source reports progressively reduced symptoms; not a validated clinical response timeline.13
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Duration of use
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 38 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 17 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 13 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “2773 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | 200-300 mcg | Once daily | General Anti-InflammatoryReference report | 4-8 weeks | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Injectable | |||||
| SubQ | 250 mcg | Twice daily | Active InflammationReference report | 4-8 weeks | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Injectable | |||||
| SubQ | 500 mcg | Once daily | Autoimmune SupportReference report | 4-8 weeks | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Injectable | |||||
| SubQ | 500 mcg | Twice daily for 1 week then reduce | Acute Flare-upsReference report | 4-8 weeks | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Injectable | |||||
| Oral | 200 mcg | Twice daily | Mild Gut InflammationReference report | 4-12 weeks | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Oral | |||||
| Oral | 300-500 mcg | 3 times daily | IBD/IBSReference report | 4-12 weeks | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Oral | |||||
| OralOral with meals | 500 mcg | 3 times daily | Acute FlaresReference report | 4-12 weeks | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Oral | |||||
| Topical | 0.1% cream | Twice daily | Mild InflammationReference report | Use as needed | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Topical | |||||
| OtherAffected areas | 0.3-0.5% cream | 2-3 times daily | Psoriasis/EczemaReference report | Use as needed | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Topical | |||||
| IntranasalNasal spray | 100-200 mcg | Twice daily | Nasal InflammationReference report | 4-8 weeks | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Nasal | |||||
| IntranasalNasal spray | 200-300 mcg | 3 times daily | Chronic SinusitisReference report | 4-8 weeks | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy. Source tabs Nasal | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 4-8 weeks
- Break
- 2-4 weeks to assess baseline inflammation
Reported timing
Can be taken any time; some prefer morning for anti-inflammatory effects
Oral
- Use period
- 4-12 weeks
- Break
- Optional 2-4 week breaks
Reported timing
With meals for best tolerance, or empty stomach for maximum effect
Topical
- Use period
- Use as needed
- Break
- Not required
Reported timing
After cleansing, can be used under moisturizer
Nasal
- Use period
- 4-8 weeks
- Break
- As needed based on symptoms
Reported timing
Morning and evening, additional dose midday if needed
Animal and cell protocols 1
Laboratory exposures cannot establish a human dose.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| OralOral (mouse drinking water) | Not specified | Not specified | Experimental colitis and inflammatory signalingAnimals | Not specified | 1 |
Population DSS/TNBS mouse models and cultured human-derived cells Context Preclinical experiment, not a human regimen. Source route wording Mouse drinking water and in-vitro cell exposure | |||||
| CellsIn vitro cell exposure | Not specified | Not specified | Experimental colitis and inflammatory signalingCells | Not specified | 1 |
Population DSS/TNBS mouse models and cultured human-derived cells Context Preclinical experiment, not a human regimen. Source route wording Mouse drinking water and in-vitro cell exposure | |||||
No protocols match these filters.
Side effects & safety
Human safety gap
FDA identified no human exposure dataset for KPV drug products.
2Formulation uncertainty
FDA notes inconsistencies in identity information and insufficient impurity characterization in submitted materials.
3Animal findings have limits
Mouse inflammation results do not quantify human adverse effects or long-term safety.
1Safety uncertainty
Source's 'excellent safety' and non-immunosuppression claims exceed established human evidence.
Stop symptoms
Fever/chills, worsening inflammation, severe local reaction, allergy or unusual weakness.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
6 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Melanotan II
Caution reportedShared α-MSH origin does not prove redundancy or interaction.13
Reference report · Pep-Pedia label: Use CautionBPC-157
Unverified pairingProposed gut-repair complement.13
Reference report · Pep-Pedia label: SynergisticTB-500
Unverified pairingUntested inflammatory pairing.13
Reference report · Pep-Pedia label: CompatibleLL-37
Unverified pairingTheoretical antimicrobial complement.13
Reference report · Pep-Pedia label: SynergisticThymosin alpha-1
Unverified pairingUntested immune pairing.13
Reference report · Pep-Pedia label: CompatibleGHK-Cu
Unverified pairingComponent-based skin hypothesis.13
Reference report · Evidence context: Synergistic for skinNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
No injectable product instruction is established by the cited research.37
Form and stability matter
FDA distinguishes free-base and acetate materials and notes formulation-dependent degradation and aggregation. Catalog storage claims do not establish clinical stability.3
Research-vial limitation
The 10 mg catalog listing alone does not supply a validated diluent volume or beyond-use date.7
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source reports two examples for a 1 mg vial.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- 1 mL gives 1,000 mcg/mL; 2 mL gives 500 mcg/mL.
Oral
This route tab repeats the injectable 1 mg vial examples.
The repeated text does not establish compatibility or stability for the selected oral, topical or nasal formulation.
Topical
This route tab repeats the injectable 1 mg vial examples.
The repeated text does not establish compatibility or stability for the selected oral, topical or nasal formulation.
Nasal
This route tab repeats the injectable 1 mg vial examples.
The repeated text does not establish compatibility or stability for the selected oral, topical or nasal formulation.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceHigh purity essentialReported appearanceClear solutionReported appearanceStable peptideReported variationProper pHReported concernVisible particlesReported concernYellow coloration
13Vial sizes
10mg7
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
13Refrigerate after reconstitution, stable for 30-45 days
Keep oral solution refrigerated, use within 24 hours of mixing
Room temperature, away from heat and light
Refrigerate nasal solution, use within 14 days
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
PreclinicalSource context
Compatibility and synergy labels are source claims, not combination trials; source ratings do not establish comparative efficacy.
Compound identity & other names
A three-amino-acid fragment related to alpha-MSH, studied for inflammatory signaling and intestinal inflammation. Cell and mouse findings have not established a human treatment dose or clinical benefit.
Other names: Lys-Pro-Val · Lysine proline valine · α-MSH fragment · Alpha-MSH fragment
No FDA-approved KPV product.
How it may work
Proposed intracellular NF-κB modulation; local oral, skin and nasal delivery claims need route-specific evidence.13
Inflammatory signaling changed in cell models
KPV reduced NF-κB/MAPK pathway activation and cytokine secretion in laboratory intestinal and immune cells; PepT1 mediated uptake. These are mechanistic endpoints.
1Colitis findings were in mice
KPV delivered in drinking water reduced inflammatory measures in DSS- and TNBS-induced mouse colitis. This does not demonstrate treatment of human IBD or validate injection.
1KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling
At 100 μg/mL, cultured-cell lipid readouts decreased. Oral administration in high-fat-diet mice changed weight gain and lipid measures; no human metabolic benefit is established.
4Research areas and evidence gaps
Intestinal inflammation research. Cell and mouse colitis experiments investigate anti-inflammatory activity.1
- Human efficacy, absorption, dose-response, and long-term safety.
- Whether oral, topical, and injected products produce comparable exposures.
Community reports Unvalidated
Self-reports describe gut symptoms and inflammatory complaints. One recent account combined KPV with BPC-157, so effects cannot be assigned to KPV.56
Self-selected accounts, uncertain diagnoses, concurrent compounds, and unverified products prevent causal conclusions.
Search coverage and review status
Additional recent evidence was checked, including KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling. See individual source summaries for findings and limitations.
- Checked
- 2026-10-12
- Search
- KPV peptide 2025 2026
- Catalog
- Pep-Pedia ↗ · 4 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationAbstract checked
AI-PREPARED SUMMARY
Cell and mouse experiments linked PepT1 uptake to reduced inflammatory signaling and colitis measures. No people were treated; neither human dosing nor injection benefit follows.
Inflammatory signaling changed in cell models
KPV reduced NF-κB/MAPK pathway activation and cytokine secretion in laboratory intestinal and immune cells; PepT1 mediated uptake. These are mechanistic endpoints.
Colitis findings were in mice
KPV delivered in drinking water reduced inflammatory measures in DSS- and TNBS-induced mouse colitis. This does not demonstrate treatment of human IBD or validate injection.
2FDA: compounding safety concernsPrimary source checked
AI-PREPARED SUMMARY
FDA reports no identified human exposure data for KPV-containing drugs.
3FDA assessment of KPV free base and acetatePrimary source checked
AI-PREPARED SUMMARY
Distinguishes the chemical forms, describes quality and formulation uncertainties, and reviews the sparse clinical evidence. This assessment is not an approved product label.
4KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signalingAbstract checked
AI-PREPARED SUMMARY
KPV affected adipogenesis in 3T3-L1 cells and metabolic measures in high-fat-diet mice. Human weight loss was not tested.
KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling
At 100 μg/mL, cultured-cell lipid readouts decreased. Oral administration in high-fat-diet mice changed weight gain and lipid measures; no human metabolic benefit is established.
Additional research · Checked 2026-10-12
5Pep-Pedia: kpv community protocol referenceCommunity source checked
AI-PREPARED SUMMARY
A secondary description of commonly discussed injection schedules, not controlled human evidence.
6Reddit: experience with KPV and BPC-157Community source checked
AI-PREPARED SUMMARY
One poster reports improved gut symptoms while combining compounds and taking 250–500 mcg KPV nightly. No objective comparison or product verification.
7Chubby Rabbit Labs KPV 10 mg listingCatalog checked
AI-PREPARED SUMMARY
Lists a 10 mg research configuration and states no verified lot-specific documentation is available. Nominal quantity only.
8Antimicrobial Properties Against Gut Pathogens (2022)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source claims antibacterial selectivity in culture; preservation of an intact human microbiome is not established by such assays.
Reported population / model
In vitro
Reported study details
Multiple bacterial strains · MIC determination
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9KPV for Psoriasis and Dermatitis (2021)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Laboratory skin models reportedly showed a 60% reduction in psoriasis-related markers; no patient clinical efficacy is established by the card.
Reported population / model
Human cells + Animal model
Reported study details
Topical application · 4 weeks
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Anti-Inflammatory Mechanisms of KPV (2020)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Cell experiments are described as showing reduced NF-κB signaling and inflammatory cytokine transcription.
Reported population / model
In vitro
Reported study details
Various concentrations · Cell culture studies
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11KPV in Inflammatory Bowel Disease Models (2019)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Animal colitis experiments reportedly improved inflammatory and intestinal-barrier measures; human IBD efficacy remains a separate question.
Reported population / model
Animal model
Reported study details
Oral and injection · 14 days · Colitis model
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Pep-Pedia: KPV — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 30 min and a peak time of 3 min. Stated attribution: Limited data. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
13Pep-Pedia: KPV — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12